Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 USD | -1.35% | +0.76% | 0.00% |
05-14 | Metagenomi, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-07 | HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target | MT |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 250.6 | - | - |
Enterprise Value (EV) 1 | 250.6 | 250.6 | 250.6 |
P/E ratio | -1.95 x | -2.02 x | -2.72 x |
Yield | - | - | - |
Capitalization / Revenue | 6.37 x | 7.97 x | 5.27 x |
EV / Revenue | 6.37 x | 7.97 x | 5.27 x |
EV / EBITDA | -2.16 x | -1.62 x | - |
EV / FCF | -6.11 x | -2.73 x | -4.31 x |
FCF Yield | -16.4% | -36.6% | -23.2% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 37,464 | - | - |
Reference price 2 | 6.560 | 6.560 | 6.560 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | 44.76 | 39.33 | 31.45 | 47.54 |
EBITDA 1 | - | -74.28 | -115.8 | -154.5 | - |
EBIT 1 | - | -78.49 | -121.2 | -146 | -154.6 |
Operating Margin | - | -175.38% | -308.17% | -464.37% | -325.08% |
Earnings before Tax (EBT) 1 | - | -60.23 | -110.3 | -141.5 | -154.6 |
Net income 1 | -43.59 | -68.26 | -111.9 | -143.5 | -158.6 |
Net margin | - | -152.5% | -284.43% | -456.32% | -333.53% |
EPS 2 | -12.82 | -35.03 | -3.359 | -3.248 | -2.413 |
Free Cash Flow 1 | - | -101.2 | -41 | -91.8 | -58.1 |
FCF margin | - | -226.17% | -104.25% | -291.91% | -122.2% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 03/08/23 | 27/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|
Net sales 1 | 12.4 | 11.16 | 10.98 | 7.375 | 7.375 | 11 | 11 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | -20.2 | -29.03 | -27.87 | -32.46 | -32.9 | -30.45 | -30.9 |
Operating Margin | -162.88% | -260.17% | -253.97% | -440.17% | -446.13% | -276.82% | -280.91% |
Earnings before Tax (EBT) 1 | -16.57 | -25.15 | -26.18 | -30.85 | -31.4 | -27.86 | -28.54 |
Net income 1 | -19.29 | -25.15 | -26.18 | -30.85 | -31.4 | -27.86 | -28.54 |
Net margin | -155.61% | -225.36% | -238.54% | -418.31% | -425.73% | -253.29% | -259.5% |
EPS 2 | -9.905 | -2.079 | -0.5828 | -0.8113 | -0.8313 | -0.7900 | -0.8200 |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 27/03/24 | 14/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -101 | -41 | -91.8 | -58.1 |
ROE (net income / shareholders' equity) | - | - | -44.6% | -107% | - |
ROA (Net income/ Total Assets) | - | -17.5% | -26.2% | -51.4% | - |
Assets 1 | - | 389.6 | 427 | 279.4 | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 9.81 | 15 | 14 | 14 |
Capex / Sales | - | 21.93% | 38.14% | 44.54% | 29.45% |
Announcement Date | 03/08/23 | 27/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 251M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- MGX Stock
- Financials Metagenomi, Inc.